Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities

Bridging the Biomarker Chasm With Interprofessional Molecular Tumor Boards

“…We recently read the editorial “Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities” by West and Lovly 1 and agree with the important points raised in their discussion. They highlighted the benefits and challenges related to implementing prospective biomarker testing into routine clinical practice.…”

ChatGPT—A promising generative AI tool and its implications for cancer care

“…Although it is possible to take some of this process out of the hands of oncologists by having NGS reports interpreted by molecular pathologists, molecular oncologists, and other dedicated experts running molecular tumor boards or offering commentary on NGS reports for clinical oncologists as a service, these approaches fail to scale to meet the demand of the majority of patients with a wide range of cancer types who need biomarker testing and interpretation. 4 Whereas we are far from having a subspecialist workforce available to provide universal support for biomarker interpretation, ChatGPT can be informed by the most expert level of interpretation and identification of clinically relevant biomarkers and then used to interpret oncology NGS reports and make appropriate recommendations. To this end, ChatGPT is expected to learn the real correlation between mutations (biomarkers) and treatment drugs, which is then validated by the human oncologist.…”

Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports

“…We read with interest and enthusiasm the recent editorial “Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities” by West and Lovly. 1 Their editorial highlights the fact that integration of molecular biomarkers into treatment decision making, including next-generation sequencing (NGS) of tumor tissue or circulating tumor DNA, has transformed cancer care. West and Lovly, along with others, have identified challenges that may prevent oncologists from reliably translating biomarker results into optimal treatment plans for patients and propose potential solutions to help overcome these barriers.…”